Related references
Note: Only part of the references are listed.Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment
Claudia Campana et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
Mari C. Vazquez-Borrego et al.
CLINICAL CANCER RESEARCH (2020)
Pituitary-Tumor Endocrinopathies
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Octreotide-Resistant Acromegaly: Challenges and Solutions
Giuliana Corica et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine
Guido Rindi et al.
NATURE REVIEWS ENDOCRINOLOGY (2020)
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study
Sabrina Chiloiro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
Federico Gatto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness
Pedro Marques et al.
ENDOCRINE-RELATED CANCER (2019)
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression
Ammar Muhammad et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells
Federico Gatto et al.
PITUITARY (2019)
A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment
E. Peverelli et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity
Monica Gatti et al.
EXPERIMENTAL CELL RESEARCH (2018)
cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells
E. Peverelli et al.
CANCER LETTERS (2018)
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
Thomas Guenther et al.
PHARMACOLOGICAL REVIEWS (2018)
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas
Roberto Wuerth et al.
MOLECULAR NEUROBIOLOGY (2017)
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas
Federico Gatto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease
Masanori Kugita et al.
PLOS ONE (2017)
Different Effects of Human Umbilical Cord Mesenchymal Stem Cells on Glioblastoma Stem Cells by Direct Cell Interaction or Via Released Soluble Factors
Adriana Bajetto et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2017)
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study
Donato Iacovazzo et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells
Thomas Cuny et al.
ENDOCRINE-RELATED CANCER (2016)
Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro
Alejandro Ibanez-Costa et al.
JOURNAL OF ENDOCRINOLOGY (2016)
Somatostatin receptor 1-5; expression profiles during rat development
Eva Ludvigsen et al.
UPSALA JOURNAL OF MEDICAL SCIENCES (2015)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Somatostatin receptor ligands and resistance to treatment in pituitary adenomas
Daniel Cuevas-Ramos et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: Effect of mono- and bi-specific somatostatin analogs on cell growth
M. Ruscica et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly
Andrea Giustina et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up
Jacqueline Trouillas et al.
ACTA NEUROPATHOLOGICA (2013)
Somatostatin receptors: From signaling to clinical practice
Marily Theodoropoulou et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2013)
Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide
Olivera Casar-Borota et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly
Federico Gatto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Effects of somatostatin analogs on glucose homeostasis in rats
Herbert A. Schmid et al.
JOURNAL OF ENDOCRINOLOGY (2012)
Structural Determinants of Agonist-Selective Signaling at the sst2A Somatostatin Receptor
Falko Nagel et al.
MOLECULAR ENDOCRINOLOGY (2011)
Ligand-Dependent Mechanisms of sst2A Receptor Trafficking: Role of Site-Specific Phosphorylation and Receptor Activation in the Actions of Biased Somatostatin Agonists
Yachu J. Kao et al.
MOLECULAR ENDOCRINOLOGY (2011)
Regulation of prostate cancer cell proliferation by somatostatin receptor activation
Massimiliano Ruscica et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Pasireotide and Octreotide Stimulate Distinct Patterns of sst2A Somatostatin Receptor Phosphorylation
Florian Poell et al.
MOLECULAR ENDOCRINOLOGY (2010)
Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways
Renzo Cescato et al.
MOLECULAR ENDOCRINOLOGY (2010)
Pituitary somatostatin receptor signaling
Anat Ben-Shlomo et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Differential Ligand-Mediated Pituitary Somatostatin Receptor Subtype Signaling: Implications for Corticotroph Tumor Therapy
Anat Ben-Shlomo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro
Sarah Lesche et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Site Specificity of Agonist and Second Messenger-Activated Kinases for Somatostatin Receptor Subtype 2A (Sst2A) Phosphorylation
Qisheng Liu et al.
MOLECULAR PHARMACOLOGY (2009)
Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-η-dependent inhibition of extracellularly regulated kinase-1/2
Federica Barbieri et al.
ENDOCRINOLOGY (2008)
Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
Giselle F. Taboada et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors
Tullio Florio
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas
Ursula Ploeckinger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Somatostatin agonists for treatment of acromegaly
Anat Ben-Shlomo et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion
Maria Chiara Zatelli et al.
ENDOCRINE-RELATED CANCER (2007)
Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours
Erika Hubina et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Chemokine stromal cell-derived factor 1α induces proliferation and growth hormone release in GH4C1 rat pituitary adenoma cell line through multiple intracellular signals
T Florio et al.
MOLECULAR PHARMACOLOGY (2006)
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro
LJ Hofland et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion
RD Murray et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Evidence for differential effects of selective somatostatin receptor subtype agonists on α-subunit and chromogranin A secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro
MC Zatelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion
SG Ren et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro
T Florio et al.
CLINICAL ENDOCRINOLOGY (2003)
Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: Effects on cell viability, GH, and PRL secretion
MC Zatelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities
T Florio et al.
ENDOCRINOLOGY (2003)
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
C Bruns et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT
MC Zatelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor ST1571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
J Topaly et al.
LEUKEMIA (2001)
Human somatostatin receptor subtypes in acromegaly: Distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes
P Jaquet et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Share Paper
